Table 1.
Patient baseline characteristics and survival—affected (patients who developed MAHA) vs unaffected (patients without MAHA).
| Affected (n = 11) 35.5% | Unaffected (n = 20) 64.5% | |
|---|---|---|
| Mean age | 72 | 64 |
| Male | 8 | 10 |
| Female | 3 | 10 |
| Ethnicities |
Caucasian/European (8) South East Asian (1) South Asian (1) South American (1) |
Caucasian/European (13) South East Asian (1) South Asian (1) Middle Eastern (4) African (1) |
| Myeloma immunophenotype |
IgG (6) IgA (4) Light chain (1) |
IgG (10) IgA (2) IgD (1) Light chain (6) Non-secretory (1) |
| No. of prior treatment lines including autograft (no. of patients) |
2 (2) 3 (4) 4 (1) 5 (2) 8 (1) |
2 (2) 3 (8) 4 (4) 5 (3) 6 (1) 7 (2) |
| Median no. of prior lines | 3 | 3.5 |
| Median OS | 21 months | 21.5 months |
OS overall survival from carfilzomib commencement.